B of A Securities Maintains Buy on Vertex Pharmaceuticals, Lowers Price Target to $541

Benzinga · 10/14 17:48
B of A Securities analyst Ying Huang maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and lowers the price target from $550 to $541.